Current stock page

Financial Data

TSHA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TSHATaysha Gene Therapies, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$4.10−$0.11 (−2.61%)

Latest quote

  • Momentum
    32
  • Value
    —
  • Quality
    37
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$5.49M$0$1.99M$2.3M$2.02M
Gross Profit$0$0-$295K$5.19M-$286K$1.99M$2.3M$2.02M
Operating Income-$41.87M-$47.35M-$43.49M-$28.3M-$34.02M-$26.75M-$21.42M-$19.93M
Net Income-$39.13M-$46.64M-$42.41M-$27.85M-$32.73M-$26.88M-$21.53M-$18.79M
EPS-$0.1-$0.13-$0.12-$0.08-$0.09-$0.09-$0.08-$0.09
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$32.91M-$40.43M-$40.88M-$26.72M-$24.17M-$20.18M-$22.02M-$18.31M
Capital Expenditure-$443K$1K-$3.02M-$250K-$108K-$2K-$378K$2K
Free Cash Flow-$33.36M-$40.42M-$43.9M-$26.97M-$24.27M-$20.18M-$22.4M-$18.31M
Net Cash Provided By Operating Activities-$32.91M-$40.43M-$40.88M-$26.72M-$24.17M-$20.18M-$22.02M-$18.31M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$435.03M$470.43M$300.35M$343.32M$316.55M$333.33M$138.36M$160.36M
Total Debt$54.59M$55.55M$17.77M$18.17M$69.08M$59.6M$61.35M$63.18M
Cash And Cash Equivalents$422.83M$455.41M$276.58M$319.77M$297.34M$312.76M$116.59M$139.04M
Total Liabilities$78.06M$83.17M$88.41M$96.38M$97.57M$84.6M$83.3M$88.84M
Total Stockholders Equity$356.97M$387.27M$211.94M$246.94M$218.99M$248.73M$55.06M$71.53M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.666.3712.075.96.893.4912.524.64
P/S ratio303.56———————
Debt To Equity0.150.140.080.070.320.241.110.88
Free Cash Flow Yield-8.69%-5.50%-4.51%-6.44%-5.64%-9.52%-12.19%-24.58%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.666.3712.075.96.893.4912.524.64
P/S ratio303.56———————
Return On Equity-43.71%-38.64%-61.28%-44.14%-45.63%-37.28%-157.59%-124.85%
Debt To Equity0.150.140.080.070.320.241.110.88

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-9.53x
Pb4.66x
EPS Growth Yoy-7.99%
Gross Margin89.17%
Operating Margin-2935.41%
ROE-51.87%
ROIC-38.96%
Debt To Equity0.15
FCF Yield-10.86%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$4.10
Volume2.47M
RSI (14)44.68
MACD-0.06
MACD signal-0.1
MACD histogram0.04
ADX (14)15.07
SMA (50)$4.49
SMA (200)$5.30
ATR (14)$0.29
Historical volatility (annualized)61.47%
Volume (20-day average)3.46M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score37/100
Beta1.73
Annual volatility70.69%
Max Drawdown-49.71%
Sharpe Ratio0.32
VaR (95%, 1-day)-6.50%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TSHA Financial Data FAQ

What is Taysha Gene Therapies, Inc.'s revenue?

Taysha Gene Therapies, Inc.'s revenue is one of the core financial data points for TSHA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Taysha Gene Therapies, Inc.'s revenue growing?

Revenue growth shows whether Taysha Gene Therapies, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TSHA's EPS?

TSHA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Taysha Gene Therapies, Inc.'s net income?

Taysha Gene Therapies, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Taysha Gene Therapies, Inc. generate?

Free cash flow shows how much cash Taysha Gene Therapies, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Taysha Gene Therapies, Inc. have?

Cash and debt help frame TSHA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.